GlassScriptPhysician profile
Michael N Kang
NPI 1659383610
$429,077.22
in general payments reported to CMS, 2019-2025
10 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92K · 2020: $39K · 2021: $296K · 2022: $565 · 2023: $343 · 2024: $681 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.03 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, LP | $251,160.10 | 2019-2021 | |
| Exactech, INC. | $176,217.50 | 2019-2024 | |
| Zimmer Biomet Holdings, INC. | $899.83 | 2019-2025 | Persona, G7 |
| Depuy Synthes Sales INC. | $332.76 | 2019-2025 | Teligen, Orthovisc, Monovisc |
| Relievant Medsystems, INC. | $120.32 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $106.08 | 2020-2024 | Caldolor |
| Merck Sharp & Dohme LLC | $94.32 | 2019-2025 | Bridion, Verquvo |
| Globus Medical, INC. | $91.47 | 2021 | |
| Heron Therapeutics, INC. | $33.44 | 2025 | Aponvie |
| Convatec INC. | $21.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.